Cytokinetics' ispinesip flunks another trial

Cytokinetics has announced that a Phase II trial of ispinesib for head and neck cancer failed to hits its primary endpoint. The best overall response trial was disease stabilization, which was observed in 5 of the 19 patients. In a press release, the company said the results didn't justify moving ispinesip on to further trials. Back in March Cytokinetics determined that inpinesib didn't demonstrate sufficient anti-tumor activity to justify moving on to the next step in a mid-stage study. Cytokinetics is developing the drug with GlaxoSmithKline.

- see the company press release

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.